2015 Fiscal Year Final Research Report
The challenge to develop a new BCG immunotherapy against non-muscle invasive bladder cancer
| Project/Area Number |
26861274
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | 膀胱癌 / BCG |
|---|
| Outline of Final Research Achievements |
BCG is used for the treatment of bladder cancer. The recruitment of neutrophlis to the bladder after BCG instillation exerts anti-tumor activity against bladder tumor. We have recently demonstrated that interleukin (IL)-17A produced by gamma-delta (gd) T cells played a role in the recruitment of neutrophlis to the bladder after BCG instillation. We previously constructed a recombinant BCG strain expressing the fusion protein of IL-15 and Ag85B (BCG-IL-15) for prevention of Mycobacterium tuberculosis infection. Here we compared the efficacy of the BCG-IL-15 in protection against bladder cancer with that of rBCG-Ag85B (BCG).
BCG-IL-15 treatment significantly prolonged survival of mice inoculated with bladder cancer cells compared with BCG treatment. Infiltration of neutrophils was significantly elevated in BCG-IL-15 treated mice accompanied by increased chemokinesin the bladder. Thus, BCG-IL-15 exerted additive effect on Infiltration of neutrophils in the bladder.
|
| Free Research Field |
泌尿器がん
|
